Increasing Survival of Patients with Severe SARS-CoV-2 Infection and/or Multi Organ Failure by up to 30% with ADVOS - ADVanced Organ Support
- Funded by European Commission
- Total publications:0 publications
Grant number: 961745
Grant search
Key facts
Disease
COVID-19Start & end year
20202023Known Financial Commitments (USD)
$1,123,296.28Funder
European CommissionPrincipal Investigator
Droller DavidResearch Location
GermanyLead Research Institution
ADVITOS GMBHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
Innovation
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
ADVITOS` innovation 'Äì the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patient with MOF is being treated with ADVOS in Germany at present with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion (2.3m'Ǩ grant). Following the urgent EU call for corona solutions, we apply now for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources as well as accelerated clinical evidence for medical indication guidance. Integrating fluid-based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the 1st and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current Corona crisis. The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile). This relates especially to the removal of CO2 (by ADVOS) which relieves the lung and reduces the need/invasiveness of ventilation.